New advances in medical imaging technology for the evaluation of anthracycline-induced cardiotoxicity
- PMID: 36195994
- PMCID: PMC9521788
- DOI: 10.1097/CM9.0000000000002123
New advances in medical imaging technology for the evaluation of anthracycline-induced cardiotoxicity
Conflict of interest statement
None.
References
-
- Otterstad JE, Froeland G, St John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 1997; 18:507–513. doi: 10.1093/oxfordjournals.eurheartj.a015273. - PubMed
-
- de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Bejarano Hernandez S, et al. . Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrex-ate-, fluorouracil- or epirubicin-based chemotherapy. Eur J Cancer 2015; 51:2517–2524. doi: 10.1016/j.ejca.2015.08.011. - PubMed
-
- Farhad H, Staziaki PV, Addison D, Coelho-Filho OR, Shah RV, Mitchell RN, et al. . Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 2016; 9:e003584.doi: 10.1161/CIRCIMAGING.115.003584. - PMC - PubMed
-
- Jordan JH, D’Agostino RB, Jr, Hamilton CA, Vasu S, Hall ME, Kitzman DW, et al. . Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2014; 7:872–879. doi: 10.1161/CIRCIMAGING.114.002217. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources